Amgen Inc
AMGN
Key stats
- Open
- 471.86
- Day high
- 474.00
- Day low
- 466.92
- Previous close
- 468.11
- Volume
- 2.83M
- VWAP
- 467.81
- 52-week high
- 483.99
- 52-week low
- 312.39
- Market cap
- 253.21B
- Shares out
- 540.91M
- Employees
- 31,500
- Listed
- 1983
About Amgen Inc
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · THOUSAND OAKS, CA · amgen.com
Options · expiring Nov 13
Nov 12, 4:00 PM ET- Call open interest
- 2.1K
- Put open interest
- 1.3K
- Put/call
- 0.64
- At-the-money IV
- 36.9%
| Contract | Last | Traded | Volume | Open int. | IV |
|---|---|---|---|---|---|
| 492.50 put | 32.23 | Nov 6, 2:00 PM | 684 | 0 | 47.0% |
| 495 put | 34.57 | Nov 6, 2:00 PM | 684 | 153 | 50.7% |
| 470 call | 2.41 | Nov 12, 3:51 PM | 85 | 193 | 40.3% |
| 487.50 call | 0.65 | Nov 9, 12:36 PM | 73 | 133 | 70.0% |
| 445 put | 0.07 | Nov 12, 1:11 PM | 68 | 34 | 45.2% |
| 507.50 call | 0.03 | Nov 12, 3:48 PM | 64 | 101 | 79.6% |
Quarterly results
Massive · Nov 4, 2026| Q3 2026 to Sep 30, 2026 | Q2 2026 to Jun 30, 2026 | Q1 2026 to Mar 31, 2026 | Q4 2025 to Dec 31, 2025 | |
|---|---|---|---|---|
| Revenue | $10.37B | $10.05B | $8.62B | $9.87B |
| Gross profit | $7.58B | $7.24B | $5.87B | $6.89B |
| Operating income | $3.71B | $3.51B | $2.67B | $2.72B |
| Net income | $3.86B | $2.38B | $1.82B | $1.33B |
| Diluted EPS | 7.08 | 4.37 | 3.34 | 2.45 |
| Operating cash flow | $4.24B | $4.00B | $2.19B | $1.60B |
| Assets | $96.05B | $95.64B | $92.50B | $90.59B |
| Liabilities | $81.70B | $83.95B | $83.31B | $81.93B |
| Equity | $14.35B | $11.69B | $9.19B | $8.66B |
Technicals
Massive · Nov 12, 2026- 50-day average424.87
- 200-day average380.39
- RSI (14 days)62.9
Short interest
Massive · Oct 30, 2026- Oct 30, 202612.59M shares · 5.0 days to cover
- Oct 15, 202613.38M shares · 5.0 days to cover
- Sep 30, 202614.03M shares · 4.1 days to cover
- Sep 15, 202614.06M shares · 4.9 days to cover
Dividends
Massive · Nov 20, 2026- Ex Nov 20, 2026, paid Dec 11, 20262.5200 · 4 a year
- Ex Aug 21, 2026, paid Sep 11, 20262.5200 · 4 a year
- Ex May 15, 2026, paid Jun 5, 20262.5200 · 4 a year
- Ex Feb 13, 2026, paid Mar 6, 20262.5200 · 4 a year
- Ex Nov 21, 2025, paid Dec 12, 20252.3800 · 4 a year
- Ex Aug 22, 2025, paid Sep 12, 20252.3800 · 4 a year
- Ex May 16, 2025, paid Jun 6, 20252.3800 · 4 a year
- Ex Feb 14, 2025, paid Mar 7, 20252.3800 · 4 a year
Related companies
MassiveNews coverage
No stories about Amgen Inc right now.